William Blair has hand-picked its top five stock recommendations for 2026, selections that include three clinical-stage ...

Adding another potential wrinkle to the industry’s work with China is the Biosecure Act, a piece of China-targeting national ...

Mirum's recent jump lifted it past a 74.96 entry of a pattern resembling a double-bottom base. It also broke out of a ...

French biotech (ABVX) has emerged as the most likely acquisition target among biotechs in 2026, significantly outpacing others, while liver drug developer Madrigal Pharmaceuticals (MDGL) has become ...

TrinScreen HIV order signals renewed strength in global HIV testing market - Company also reports a key milestone of Adjusted EBITDA(1) positive operations in Q3 2025 and expects to achieve strong ...

One of the biotech industry’s most esteemed venture capitalists anticipates that, after two years of drought, a wave of drug ...

Philadelphia has lagged in biotech R&D jobs despite University of Pennsylvania scientists playing a leading role in ...

Something remarkable is happening in Chinese biotech, and it’s happening fast. The country’s drug developers are learning to ...

Take a look back into biotech in 2025 as the year is closing - from GLP-1s to radiopharmaceuticals and neuroplastogens.

First, the Direxion Daily S&P Biotech Bull 3X Shares (NYSE: LABU) seeks daily investment results, before fees and expenses, of 300% of the performance of the aforementioned biotech index. Second, the ...

The US Congress is poised to enact bipartisan legislation that would block some Chinese biotechnology companies from government-funded contracts and authorize the Trump administration to bar US ...

Discover how intellectual property rights protect exclusive pharmaceutical use and brand names in biotechnology, influencing innovation and market dynamics.